News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
371,670 Results
Type
Article (23063)
Company Profile (117)
Press Release (348490)
Multimedia
Podcasts (54)
Webinars (10)
Section
Business (114406)
Career Advice (959)
Deals (20525)
Drug Delivery (79)
Drug Development (50959)
Employer Resources (95)
FDA (8777)
Job Trends (8470)
News (198946)
Policy (18420)
Tag
Academia (1342)
Academic (1)
Accelerated approval (2)
Adcomms (9)
Allergies (55)
Alliances (30140)
ALS (57)
Alzheimer's disease (689)
Antibody-drug conjugate (ADC) (55)
Approvals (8803)
Artificial intelligence (148)
Autoimmune disease (13)
Automation (7)
Bankruptcy (181)
Best Places to Work (6335)
BIOSECURE Act (11)
Biosimilars (68)
Biotechnology (50)
Bladder cancer (35)
Brain cancer (17)
Breast cancer (134)
Cancer (1027)
Cardiovascular disease (114)
Career advice (817)
Career pathing (21)
CAR-T (61)
Cell therapy (173)
Cervical cancer (11)
Clinical research (42643)
Collaboration (439)
Compensation (169)
Complete response letters (17)
COVID-19 (1520)
CRISPR (26)
C-suite (142)
Cystic fibrosis (50)
Data (1153)
Denatured (19)
Depression (17)
Diabetes (152)
Diagnostics (2574)
Digital health (3)
Diversity (5)
Diversity, equity & inclusion (29)
Drug discovery (77)
Drug pricing (80)
Drug shortages (24)
Duchenne muscular dystrophy (53)
Earnings (40792)
Editorial (25)
Employer branding (8)
Employer resources (86)
Events (51647)
Executive appointments (491)
FDA (9402)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (2)
Funding (358)
Gene editing (50)
Generative AI (11)
Gene therapy (156)
GLP-1 (493)
Government (2090)
Grass and pollen (4)
Guidances (27)
Healthcare (7902)
Huntington's disease (9)
IgA nephropathy (18)
Immunology and inflammation (61)
Indications (18)
Infectious disease (1587)
Inflammatory bowel disease (87)
Inflation Reduction Act (7)
Influenza (24)
Intellectual property (54)
Interviews (147)
IPO (8131)
IRA (35)
Job creations (2416)
Job search strategy (728)
Kidney cancer (7)
Labor market (18)
Layoffs (234)
Leadership (10)
Legal (4382)
Liver cancer (33)
Lung cancer (130)
Lymphoma (79)
Machine learning (4)
Management (34)
Manufacturing (191)
MASH (51)
Medical device (4046)
Medtech (4049)
Mergers & acquisitions (12686)
Metabolic disorders (410)
Multiple sclerosis (51)
NASH (19)
Neurodegenerative disease (40)
Neuropsychiatric disorders (10)
Neuroscience (991)
NextGen: Class of 2025 (3115)
Non-profit (1984)
Now hiring (8)
Obesity (220)
Opinion (143)
Ovarian cancer (33)
Pain (69)
Pancreatic cancer (32)
Parkinson's disease (78)
Partnered (11)
Patents (132)
Patient recruitment (53)
Peanut (23)
People (37598)
Pharmaceutical (67)
Pharmacy benefit managers (13)
Phase I (11125)
Phase II (18423)
Phase III (15994)
Pipeline (628)
Policy (99)
Postmarket research (1819)
Preclinical (4451)
Press Release (48)
Prostate cancer (67)
Psychedelics (15)
Radiopharmaceuticals (148)
Rare diseases (232)
Real estate (3387)
Recruiting (34)
Regulatory (13127)
Reports (20)
Research institute (1277)
Resumes & cover letters (122)
Rett syndrome (1)
RNA editing (2)
RSV (23)
Schizophrenia (47)
Series A (70)
Series B (39)
Service/supplier (5)
Sickle cell disease (38)
Special edition (7)
Spinal muscular atrophy (106)
Sponsored (8)
Startups (2248)
State (2)
Stomach cancer (6)
Supply chain (39)
Tariffs (32)
The Weekly (33)
Vaccines (387)
Venture capitalists (19)
Weight loss (149)
Women's health (19)
Worklife (9)
Date
Today (79)
Last 7 days (378)
Last 30 days (1248)
Last 365 days (16470)
2025 (5318)
2024 (17694)
2023 (20082)
2022 (27229)
2021 (29114)
2020 (27971)
2019 (24070)
2018 (18624)
2017 (19168)
2016 (18476)
2015 (21949)
2014 (16755)
2013 (13797)
2012 (14962)
2011 (15671)
2010 (14042)
Location
Africa (459)
Alabama (19)
Alaska (4)
Arizona (83)
Arkansas (4)
Asia (26508)
Australia (4000)
California (2601)
Canada (1130)
China (318)
Colorado (108)
Connecticut (106)
Delaware (76)
Europe (57216)
Florida (452)
Georgia (101)
Idaho (23)
Illinois (294)
India (21)
Indiana (178)
Iowa (2)
Japan (118)
Kansas (64)
Kentucky (15)
Louisiana (7)
Maine (13)
Maryland (428)
Massachusetts (2047)
Michigan (59)
Minnesota (162)
Missouri (36)
Montana (11)
Nebraska (11)
Nevada (22)
New Hampshire (14)
New Jersey (995)
New Mexico (14)
New York (861)
North Carolina (496)
North Dakota (2)
Northern California (1098)
Ohio (82)
Oklahoma (6)
Oregon (19)
Pennsylvania (666)
Puerto Rico (8)
Rhode Island (12)
South America (709)
South Carolina (10)
Southern California (1058)
Tennessee (45)
Texas (355)
United States (10647)
Utah (53)
Virginia (94)
Washington D.C. (35)
Washington State (252)
Wisconsin (24)
371,670 Results for "simcere pharmaceutical group".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA
On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group, announced that Enlituo®, a new generation anti-epidermal growth factor receptor antibody drug developed in collaboration with Mabpharm Limited, has recently received approval from the China National Medical Administration for marketing.
June 26, 2024
·
4 min read
Press Releases
Duchesnay Pharmaceutical Group creates Advisory Board to help guide the Group’s growth and success
April 16, 2025
·
5 min read
Genetown
Simcere Pharmaceutical Group Announces Sponsored Research Agreement with Boston-based Mass General Brigham
Simcere Pharmaceutical Group Limited announced a Sponsored Research Agreement with Mass General Brigham.
June 12, 2023
·
5 min read
Press Releases
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
January 14, 2025
·
4 min read
Press Releases
AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
January 13, 2025
·
4 min read
Press Releases
Fermion and Simcere Enter into an Exclusive License and Collaboration Agreement for China’s First SSTR4 Agonist Targeting Pain
January 19, 2025
·
3 min read
Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart
Simcere Pharmaceutical Group Limited entered into an exclusive license and collaboration agreement with Connect Biopharma HongKong Limited in relation to Rademikibart, an innovative IL-4Rα monoclonal antibody.
November 23, 2023
·
3 min read
Business
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
Connect Biopharma Holdings Limited announced that two of its wholly owned subsidiaries, Connect Biopharma Hong Kong Limited and Suzhou Connect Biopharma Co., Ltd., have entered into an exclusive license and collaboration agreement with Simcere Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Ltd., to develop and commercialize Connect Biopharma’s rademikibart in Greater China.
November 21, 2023
·
6 min read
Press Releases
Simcere’s Sanbexin Emerges as Game-Changer: FDA Grants Breakthrough Therapy Designation to Sanbexin for AIS Treatment
December 16, 2024
·
5 min read
Press Releases
China NMPA approves Simcere’s Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke
December 4, 2024
·
4 min read
1 of 37,167
Next
